Video

Understanding the Hemp Farming Act of 2018

Karla Palmer, director at Hyman, Phelps, & McNamara, discusses how the Hemp Farming Act of 2018 affected hemp and CBD products.

Karla Palmer, director at Hyman, Phelps, & McNamara, discusses how the Hemp Farming Act of 2018 affected hemp and CBD products. This video was filmed at the 2019 NCPA Annual Convention in San Diego.

Karla Palmer, JD: The big issue around CBD is the Farm Bill that passed December 20th of 2018, because with the passage of the Farm Bill, hemp-extracted CBD with a THC level of less than 0.3% was not considered to be within the federal definition of marijuana anymore. So, it was deregulated by the Congress and thus by DEA. So, if it’s a CBD product with less than 0.3% THC, it’s basically free reign for sale. And although that sounds like a good thing, about 5 days after its deregulation in the federal system, then-FDA Commissioner [Scott] Gottlieb released a statement to the press stating that notwithstanding Congress’s treatment of CBD, hemp-derived CBD pursuant to the passage of the Agricultural Improvement Acts, FDA would still regulate CBD’s use as a dietary supplement and as a drug product, and it would be vigorously enforcing the laws concerning its use in both of those forms.

Related Videos
Image Credit: © Birdland - stock.adobe.com
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
Pharmacy, Advocacy, Opioid Awareness Month | Image Credit: pikselstock - stock.adobe.com
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
Pharmacists, Education, Advocacy, Opioid Awareness Month | Image Credit: Jacob Lund - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC